LSV Asset Management Reduces Holdings in Baxter International Inc. $BAX

LSV Asset Management lowered its position in Baxter International Inc. (NYSE:BAX) by 5.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,805,400 shares of the medical instruments supplier’s stock after selling 288,400 shares during the period. LSV Asset Management owned 0.94% of Baxter International worth $145,508,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Raiffeisen Bank International AG raised its position in shares of Baxter International by 24.9% in the first quarter. Raiffeisen Bank International AG now owns 95,668 shares of the medical instruments supplier’s stock valued at $3,229,000 after buying an additional 19,081 shares during the last quarter. Dodge & Cox grew its stake in Baxter International by 2.1% during the 1st quarter. Dodge & Cox now owns 51,458,925 shares of the medical instruments supplier’s stock valued at $1,761,439,000 after acquiring an additional 1,081,631 shares in the last quarter. Gabelli Funds LLC raised its holdings in Baxter International by 44.8% in the 1st quarter. Gabelli Funds LLC now owns 476,700 shares of the medical instruments supplier’s stock valued at $16,317,000 after acquiring an additional 147,500 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in Baxter International by 19.4% in the 1st quarter. Gamco Investors INC. ET AL now owns 188,673 shares of the medical instruments supplier’s stock worth $6,458,000 after purchasing an additional 30,700 shares in the last quarter. Finally, Amundi grew its position in shares of Baxter International by 9.5% in the first quarter. Amundi now owns 1,444,705 shares of the medical instruments supplier’s stock valued at $45,292,000 after purchasing an additional 125,431 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Stock Down 1.3%

Shares of NYSE:BAX opened at $18.46 on Monday. The company has a market capitalization of $9.49 billion, a price-to-earnings ratio of -61.52, a PEG ratio of 0.73 and a beta of 0.57. Baxter International Inc. has a 12-month low of $17.47 and a 12-month high of $37.74. The business has a 50-day moving average price of $21.92 and a 200 day moving average price of $26.02. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.09. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The company had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same quarter last year, the firm posted $0.80 earnings per share. Baxter International’s revenue was up 5.0% compared to the same quarter last year. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. Sell-side analysts expect that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, November 28th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, November 28th. Baxter International’s dividend payout ratio (DPR) is -103.03%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BAX shares. Wells Fargo & Company lowered their price objective on Baxter International from $33.00 to $24.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Baxter International in a report on Wednesday, October 8th. UBS Group lowered their price target on shares of Baxter International from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Barclays cut their price objective on shares of Baxter International from $41.00 to $36.00 and set an “overweight” rating for the company in a research report on Monday, August 4th. Finally, Stifel Nicolaus reduced their target price on shares of Baxter International from $25.00 to $22.00 in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Baxter International currently has an average rating of “Reduce” and a consensus price target of $23.70.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.